EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieQuerschnittstudieOpen Access

Serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: A cross-sectional exploratory study in patients at a tertiary care hospital

Aishwariya Brigit George, Abhishek Gupta, Raka Jain, Mamta Sood, Siddharth Sarkar

Indian Journal of Pharmacology · 2024

DOI: 10.4103/ijp.ijp_771_22 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Indian Journal of Pharmacology, 2024. Verfasst von Aishwariya Brigit George und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Marijuana Abuse, Schizophrenia, Tertiary Care Centers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Brain-derived neurotrophic factor (BDNF) has considerable relevance in neural growth and differentiation. It has been evaluated as a biomarker for individuals with various psychiatric disorders such as substance-related disorders and psychotic disorders. OBJECTIVE: The present study explored differences in the levels of BDNF (in serum) among subjects using cannabis (with and without schizophrenia). METHODS: This cross-sectional observational study compared the serum BDNF level in male subjects aged 18–45 years. Four groups of 20 subjects each were included: individuals with tobacco use disorder only, patients having schizophrenia, patients with cannabis use disorder, and finally patients with comorbid cannabis use disorder and schizophrenia. RESULTS: The BDNF levels were found to be significantly different across the four groups. The BDNF levels in subjects with concurrent schizophrenia and cannabis use disorder were higher than each of the other three groups (cannabis use disorder, schizophrenia, and tobacco use disorder only). CONCLUSION: We find that BDNF may be higher when cannabis use disorder and schizophrenia co-occur, as compared to either of the conditions alone. The findings should be interpreted with caution due to the low sample size and potential confounders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorMarijuana AbuseSchizophreniaTertiary Care CentersAdolescentAdultHumansMaleMiddle AgedYoung AdultBiomarkersCross-Sectional StudiesTobacco Use Disorder

Substanzen

BDNF protein, humanBiomarkersBrain-Derived Neurotrophic Factor

Autor:innen und Institutionen

  • Department of Psychiatry and National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India.

Zitieren

APA

George, A. B., Gupta, A., Jain, R., Sood, M., & Sarkar, S. (2024). Serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: A cross-sectional exploratory study in patients at a tertiary care hospital. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_771_22

Vancouver

George AB, Gupta A, Jain R, Sood M, Sarkar S. Serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: A cross-sectional exploratory study in patients at a tertiary care hospital. Indian Journal of Pharmacology. 2024. doi:10.4103/ijp.ijp_771_22

BibTeX
@article{George2024,
  author = {George, Aishwariya Brigit and Gupta, Abhishek and Jain, Raka and Sood, Mamta and Sarkar, Siddharth},
  title = {Serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: A cross-sectional exploratory study in patients at a tertiary care hospital},
  journal = {Indian Journal of Pharmacology},
  year = {2024},
  doi = {10.4103/ijp.ijp_771_22}
}
Kostenlos starten →